Marks, D. I. & Rowntree, C. Management of adults with T-cell lymphoblastic leukemia. Blood. 129, 1134–1142 (2017).
Rodriguez-Zuniga, M. J. M., Cortez-Franco, F. & Qujiano-Gomero, E. Adult T-cell leukemia/lymphoma. Review of the literature. Actas Dermosifiliogr (Engl Ed) 109, 399–407 (2018).
Brown, C. E. & Mackall, C. L. CAR T cell therapy: inroads to response and resistance. Nat. Rev. Immunol. 19, 73–74 (2019).
MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233–244 (2020).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020).
Mo, F., Mamonkin, M., Brenner, M. K. & Heslop, H. E. Taking T-cell oncotherapy off-the-shelf. Trends Immunol. 42, 261–272 (2021).
Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885–1894 (2020).
Hu, Y. et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 27, 2764–2772 (2021).
Fleischer, L. C., Spencer, H. T. & Raikar, S. S. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J. Hematol. Oncol. 12, 141 (2019).
Campana, D. et al. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 77, 1546–1554 (1991).
Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285–296 (2017).
Pan, J. et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-Human, phase I trial. J. Clin. Oncol. 39, 3340–3351 (2021).
Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase I clinical trial. Blood 140, 321–334 (2022).
Li, S. et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin. Cancer Res. 27, 1242–1246 (2021).
Chou, C. K. & Turtle, C. J. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin. Biol. Ther. 20, 653–664 (2020).
Rosshart, S. et al. Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur. J. Immunol. 38, 3354–3364 (2008).
Jung, L. K., Roy, A. K. & Chakkalath, H. R. CD7 augments T cell proliferation via the interleukin-2 autocrine pathway. Cell. Immunol. 141, 189–199 (1992).
Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci USA 99, 16168–16173 (2002).
Nata, T. et al. Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum. J. Biol. Chem. 290, 22338–22351 (2015).
Chang, H., Yeung, J., Brandwein, J. & Yi, Q. L. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk. Res. 31, 157–162 (2007).
Gomes-Silva, D. et al. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol. Ther. 27, 272–280 (2019).
Heslop, H. E. How I treat EBV lymphoproliferation. Blood 114, 4002–4008 (2009).
Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018).
Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352–359 (2018).
Xu, Y. et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J. Hematol. Oncol. 12, 49 (2019).
Mamonkin, M. et al. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol. Res. 6, 47–58 (2018).
Maciocia, P. M. et al. Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat. Med. 23, 1416–1423 (2017).
Mamonkin, M., Rouce, R. H., Tashiro, H. & Brenner, M. K. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983–992 (2015).
Hsu, C. et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 109, 5168–5177 (2007).
Kim, M. Y. et al. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. JCI Insight 6, e149819 (2021).
Greco, A. et al. Altered urinary excretion of human kininase activity in hypertension. Adv. Exp. Med. Biol. 120B, 645–649 (1979).
留言 (0)